Details
Stereochemistry | ACHIRAL |
Molecular Formula | C27H21F3N8O |
Molecular Weight | 530.5038 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CN(C=N1)C2=CC(=CC(NC(=O)C3=CC=C(C)C(NC4=NC=CC(=N4)C5=CN=CC=N5)=C3)=C2)C(F)(F)F
InChI
InChIKey=DUPWHXBITIZIKZ-UHFFFAOYSA-N
InChI=1S/C27H21F3N8O/c1-16-3-4-18(9-23(16)37-26-33-6-5-22(36-26)24-13-31-7-8-32-24)25(39)35-20-10-19(27(28,29)30)11-21(12-20)38-14-17(2)34-15-38/h3-15H,1-2H3,(H,35,39)(H,33,36,37)
Molecular Formula | C27H21F3N8O |
Molecular Weight | 530.5038 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24705186
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24705186
Radotinib (Supect) was developed and approved in Korea as a second-line Chronic Myeloid Leukemia treatment. The drug supresses cancer cells proliferation by inhibitiing BCR-ABL1 kinase which is a driver of Philadelphia chromosome-positive (Ph+) leukemia.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
250 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32095473/ |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
RADOTINIB plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 2 times / day multiple, oral Studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Hyperbilirubinemia... AEs leading to discontinuation/dose reduction: Hyperbilirubinemia (grade 3-4, 7.8%) Sources: |
800 mg 2 times / day multiple, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Other AEs: Dysplastic nevus... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hyperbilirubinemia | grade 3-4, 7.8% Disc. AE |
400 mg 2 times / day multiple, oral Studied dose Dose: 400 mg, 2 times / day Route: oral Route: multiple Dose: 400 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Dysplastic nevus | 800 mg 2 times / day multiple, oral Studied dose Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26666371
Take 300 mg or 400 mg twice daily.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26065685
Acute myeloid leukemia NB4, HL60, KASUMI-1 and THP-1 cells were incubated with various concentrations of radotinib (0, 1,10, and 100 uM) for 72 h at 37C. At 100 uM NB4 cells growth was inhibited to 18%.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:43:23 GMT 2025
by
admin
on
Mon Mar 31 19:43:23 GMT 2025
|
Record UNII |
I284LJY110
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1967
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB12323
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
C98110
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
5188
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
9242
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
DTXSID90239069
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
7814
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
SUB179788
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
16063245
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
Radotinib
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
m11723
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
I284LJY110
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
926037-48-1
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY | |||
|
100000165894
Created by
admin on Mon Mar 31 19:43:23 GMT 2025 , Edited by admin on Mon Mar 31 19:43:23 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |